Daniel Janney - Net Worth and Insider Trading

Daniel Janney Net Worth

The estimated net worth of Daniel Janney is at least $32 Million dollars as of 2026-08-16. Daniel Janney is the Director of Krystal Biotech Inc and owns about 73,293 shares of Krystal Biotech Inc (KRYS) stock worth over $24 Million. Daniel Janney is the Director of Esperion Therapeutics Inc and owns about 1,366,987 shares of Esperion Therapeutics Inc (ESPR) stock worth over $4 Million. Daniel Janney is also the Director, 10% Owner of Allakos Inc and owns about 9,050,493 shares of Allakos Inc (ALLK) stock worth over $3 Million. Besides these, Daniel Janney also holds Viveve Medical Inc (VIVE) . Details can be seen in Daniel Janney's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel Janney has not made any transactions after 2026-02-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Daniel Janney

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

KRYS Krystal Biotech Inc

77% of holdings · $24.4M

ESPR Esperion Therapeutics Inc

14% of holdings · $4.3M

9% of holdings · $3.0M

VIVE Viveve Medical Inc

Daniel Janney Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daniel Janney owns 21 companies in total, including Krystal Biotech Inc (KRYS) , Esperion Therapeutics Inc (ESPR) , and Allakos Inc (ALLK) among others .

Click here to see the complete history of Daniel Janney’s form 4 insider trades.

Insider Ownership Summary of Daniel Janney

Ticker	Company	Transaction Date	Type of Owner
KRYS	Krystal Biotech Inc	2026-02-27	director
ESPR	Esperion Therapeutics Inc	2017-03-21	director
ALLK	Allakos Inc	2022-09-21	director
		2018-09-26	director & 10 percent owner
		2017-03-17	director & 10 percent owner
		2014-11-19	director & 10 percent owner
		2015-06-05	10 percent owner
		2015-05-06	10 percent owner
		2015-04-08	10 percent owner
		2014-01-30	10 percent owner
		2014-03-26	10 percent owner
		2014-07-29	10 percent owner
		2013-10-25	10 percent owner
		2011-04-20	10 percent owner
		2011-02-10	10 percent owner
		2009-09-03	other: No longer 10% owner
		2007-05-07	10 percent owner
		2004-02-11	director
		2004-03-31	10 percent owner
		2003-08-27	10 percent owner
		2021-09-14	10 percent owner

Daniel Janney Latest Holdings Summary

Daniel Janney currently owns a total of 4 stocks. Among these stocks, Daniel Janney owns 73,293 shares of Krystal Biotech Inc (KRYS) as of February 27, 2026, with a value of $24 Million and a weighting of 76.88%. Daniel Janney owns 1,366,987 shares of Esperion Therapeutics Inc (ESPR) as of March 21, 2017, with a value of $4 Million and a weighting of 13.72%. Daniel Janney also owns 9,050,493 shares of Allakos Inc (ALLK) as of September 21, 2022, with a value of $3 Million and a weighting of 9.4%. The other 1 stocks Viveve Medical Inc (VIVE) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Daniel Janney

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KRYS	Krystal Biotech Inc	2026-02-27	73,293	332.27	24,353,065
ESPR	Esperion Therapeutics Inc	2017-03-21	1,366,987	3.18	4,347,019
ALLK	Allakos Inc	2022-09-21	9,050,493	0.33	2,978,517
VIVE	Viveve Medical Inc	2017-03-17	1,385	0.00	0

Holding Weightings of Daniel Janney

Daniel Janney Form 4 Trading Tracker

According to the SEC Form 4 filings, Daniel Janney has made a total of 7 transactions in Krystal Biotech Inc (KRYS) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in Krystal Biotech Inc is the sale of 11,803 shares on February 27, 2026, which brought Daniel Janney around $3 Million.

According to the SEC Form 4 filings, Daniel Janney has made a total of 0 transactions in Esperion Therapeutics Inc (ESPR) over the past 5 years. The most-recent trade in Esperion Therapeutics Inc is the sale of 350,000 shares on March 21, 2017, which brought Daniel Janney around $16 Million.

According to the SEC Form 4 filings, Daniel Janney has made a total of 1 transactions in Allakos Inc (ALLK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Allakos Inc is the acquisition of 475,000 shares on September 21, 2022, which cost Daniel Janney around $2 Million.

More details on Daniel Janney's insider transactions can be found in the Insider Trading History of Daniel Janney table.

Insider Trading History of Daniel Janney

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daniel Janney Trading Performance

GuruFocus tracks the stock performance after each of Daniel Janney's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel Janney is 40.48%. GuruFocus also compares Daniel Janney's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel Janney within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Daniel Janney's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Daniel Janney

Average Return

Average return per transaction

Outperforming Transactions

2 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	18.35
Relative Return to S&P 500(%)	15.93

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Daniel Janney owns.

- KRYS - ESPR - ALLK - VIVE

View KRYS Analysis

Daniel Janney Ownership Network

Ownership Network List of Daniel Janney

No Data

Ownership Network Relation of Daniel Janney

Daniel Janney Owned Company Details

What does Krystal Biotech Inc do?

Who are the key executives at Krystal Biotech Inc?

Daniel Janney is the director of Krystal Biotech Inc. Other key executives at Krystal Biotech Inc include EVP & General Counsel John Charles Thomas , director & 10 percent owner & President and CEO Krish S Krishnan , and director & 10 percent owner & Chief Operating Officer Suma Krishnan .

Krystal Biotech Inc (KRYS) Insider Trades Summary

Over the past 18 months, Daniel Janney made 2 insider transaction in Krystal Biotech Inc (KRYS) with a net sale of 71,964. Other recent insider transactions involving Krystal Biotech Inc (KRYS) include a net sale of 200,000 shares made by Krish S Krishnan , a net sale of 200,000 shares made by Suma Krishnan , and a net sale of 14,000 shares made by Kathryn Romano .

In summary, during the past 3 months, insiders sold 76,642 shares of Krystal Biotech Inc (KRYS) in total and bought 0 shares, with a net sale of 76,642 shares. During the past 18 months, 531,556 shares of Krystal Biotech Inc (KRYS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 531,556 shares.

Krystal Biotech Inc (KRYS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Krystal Biotech Inc Insider Transactions

No Available Data

What does Esperion Therapeutics Inc do?

Who are the key executives at Esperion Therapeutics Inc?

Daniel Janney is the director of Esperion Therapeutics Inc. Other key executives at Esperion Therapeutics Inc include Chief Financial Officer Benjamin Halladay , Chief Operating Officer Sheldon L. Koenig , and General Counsel Benjamin Looker .

Esperion Therapeutics Inc (ESPR) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Esperion Therapeutics Inc (ESPR). Other recent insider transactions involving Esperion Therapeutics Inc (ESPR) include a net sale of 42,374 shares made by Benjamin Halladay , a net sale of 40,979 shares made by Benjamin Looker , and a net sale of 199,358 shares made by Sheldon L. Koenig .

In summary, during the past 3 months, insiders sold 76,185 shares of Esperion Therapeutics Inc (ESPR) in total and bought 0 shares, with a net sale of 76,185 shares. During the past 18 months, 285,491 shares of Esperion Therapeutics Inc (ESPR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 285,491 shares.

Esperion Therapeutics Inc (ESPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Esperion Therapeutics Inc Insider Transactions

No Available Data

What does Allakos Inc do?

Who are the key executives at Allakos Inc?

Daniel Janney is the director of Allakos Inc. Other key executives at Allakos Inc include Chief Financial Officer Harlan Baird Radford , Chief Medical Officer Craig A. Paterson , and General Counsel and Secretary Margaret Nell Fitzgerald .

Allakos Inc (ALLK) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Allakos Inc (ALLK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Allakos Inc (ALLK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Allakos Inc (ALLK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allakos Inc Insider Transactions

No Available Data

What does Sutro Biopharma Inc do?

Who are the key executives at Sutro Biopharma Inc?

Daniel Janney is the director & 10 percent owner of Sutro Biopharma Inc. Other key executives at Sutro Biopharma Inc include Chief Admin. Ofcr. & GC David Pauling , Chief Scientific Officer Hans-peter Gerber , and CFO Gregory K. Chow .

Sutro Biopharma Inc (STRO) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Sutro Biopharma Inc (STRO). Other recent insider transactions involving Sutro Biopharma Inc (STRO) include a net purchase of 50,000 shares made by Matsui Connie , a net purchase of 19,750 shares made by Gregory K. Chow , and a net purchase of 17,000 shares made by Hans-peter Gerber .

In summary, during the past 3 months, insiders sold 0 shares of Sutro Biopharma Inc (STRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sutro Biopharma Inc (STRO) were sold and 11,175 shares were bought by its insiders, resulting in a net purchase of 11,175 shares.

Sutro Biopharma Inc (STRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sutro Biopharma Inc Insider Transactions

No Available Data

What does Viveve Medical Inc do?

Who are the key executives at Viveve Medical Inc?

Daniel Janney is the director & 10 percent owner of Viveve Medical Inc. Other key executives at Viveve Medical Inc include 10 percent owner Goldman Sachs Group Inc/ , 10 percent owner Goldman Sachs & Co , and 10 percent owner Wilmot B. Harkey .

Viveve Medical Inc (VIVE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Viveve Medical Inc (VIVE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Viveve Medical Inc (VIVE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Viveve Medical Inc (VIVE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viveve Medical Inc Insider Transactions

No Available Data

What does Evofem Biosciences Inc do?

Who are the key executives at Evofem Biosciences Inc?

Daniel Janney is the director & 10 percent owner of Evofem Biosciences Inc. Other key executives at Evofem Biosciences Inc include CFO Yan Zhang , director & 10 percent owner Kim P. Kamdar , and Chief Commercial Officer Atkinson Katherine Cocca .

Evofem Biosciences Inc (EVFM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Evofem Biosciences Inc (EVFM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Evofem Biosciences Inc (EVFM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Evofem Biosciences Inc (EVFM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evofem Biosciences Inc Insider Transactions

No Available Data

What does ZS Pharma Inc do?

Who are the key executives at ZS Pharma Inc?

Daniel Janney is the 10 percent owner of ZS Pharma Inc. Other key executives at ZS Pharma Inc include 10 percent owner Devon Park Associates, Llc , Chief Operating Officer D Jeffrey Keyser , and See Remarks Adam Tomasi .

ZS Pharma Inc (ZSPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZS Pharma Inc (ZSPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZS Pharma Inc (ZSPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZS Pharma Inc (ZSPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZS Pharma Inc Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Daniel Janney is the 10 percent owner of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , director & President and CEO Sanjay Shukla , and General Counsel Nancy Denyes .

aTyr Pharma Inc (ATYR) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 1,100,000 shares made by Paul Schimmel , a net purchase of 3,750 shares made by Jane A Gross , and a net sale of 3,745 shares made by Sanjay Shukla .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 100,000 shares, with a net purchase of 100,000 shares. During the past 18 months, 6,421 shares of aTyr Pharma Inc (ATYR) were sold and 1,103,750 shares were bought by its insiders, resulting in a net purchase of 1,097,329 shares.

aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Daniel Janney is the 10 percent owner of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Development Officer Christopher Yea , Chief Medical Officer Paul K. Audhya , and Chief Commercial Officer Nicole Sweeny .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 159,407 shares made by Benjamin L Palleiko , a net sale of 100,279 shares made by Christopher Yea , and a net sale of 44,877 shares made by Paul K. Audhya .

In summary, during the past 3 months, insiders sold 62,082 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 62,082 shares. During the past 18 months, 545,127 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 520,127 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does Trevena Inc do?

Who are the key executives at Trevena Inc?

Daniel Janney is the 10 percent owner of Trevena Inc. Other key executives at Trevena Inc include VP & Finance Katrine Sutton , director & President & CEO Carrie L. Bourdow , and SVP & Chief Medical Officer Mark Demitrack .

Trevena Inc (TRVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Trevena Inc (TRVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Trevena Inc (TRVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Trevena Inc (TRVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevena Inc Insider Transactions

No Available Data

What does Applied Genetic Technologies Corp do?

Who are the key executives at Applied Genetic Technologies Corp?

Daniel Janney is the 10 percent owner of Applied Genetic Technologies Corp. Other key executives at Applied Genetic Technologies Corp include Chief Medical Officer Susan Schneider , Chief Financial Officer Jonathan I Lieber , and See Remarks Stephen W Potter .

Applied Genetic Technologies Corp (AGTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Applied Genetic Technologies Corp (AGTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Applied Genetic Technologies Corp (AGTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Applied Genetic Technologies Corp (AGTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Applied Genetic Technologies Corp Insider Transactions

No Available Data

What does Immune Design Corp do?

Who are the key executives at Immune Design Corp?

Daniel Janney is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .

Immune Design Corp (IMDZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immune Design Corp Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Daniel Janney is the 10 percent owner of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ellie Mae Inc do?

Who are the key executives at Ellie Mae Inc?

Daniel Janney is the 10 percent owner of Ellie Mae Inc. Other key executives at Ellie Mae Inc include EVP & Technology & Operations Peter Hirsch , 10 percent owner First American Corp , and 10 percent owner Guy P Nohra .

Ellie Mae Inc (ELLI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ellie Mae Inc (ELLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ellie Mae Inc (ELLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ellie Mae Inc (ELLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ellie Mae Inc Insider Transactions

No Available Data

What does Talphera Inc do?

Who are the key executives at Talphera Inc?

Daniel Janney is the 10 percent owner of Talphera Inc. Other key executives at Talphera Inc include director & Chief Executive Officer Vincent J. Angotti , Chief Medical Officer Shakil Aslam , and Chief Engineering Officer Badri N Dasu .

Talphera Inc (TLPH) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Talphera Inc (TLPH). Other recent insider transactions involving Talphera Inc (TLPH) include a net purchase of 531,984 shares made by Vincent J. Angotti , a net purchase of 45,000 shares made by Raffi Asadorian , and a net purchase of 35,000 shares made by Badri N Dasu .

In summary, during the past 3 months, insiders sold 0 shares of Talphera Inc (TLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Talphera Inc (TLPH) were sold and 646,984 shares were bought by its insiders, resulting in a net purchase of 646,984 shares.

Talphera Inc (TLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talphera Inc Insider Transactions

No Available Data

What does Raptor Pharmaceutical Corp do?

Who are the key executives at Raptor Pharmaceutical Corp?

Daniel Janney is the other: No longer 10% owner of Raptor Pharmaceutical Corp. Other key executives at Raptor Pharmaceutical Corp include Chief Medical Officer Krishna R Polu , Chief Financial Officer Michael P Smith , and Chief Commercial Officer David Happel .

Raptor Pharmaceutical Corp (RPTP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Raptor Pharmaceutical Corp (RPTP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Raptor Pharmaceutical Corp (RPTP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Raptor Pharmaceutical Corp (RPTP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Raptor Pharmaceutical Corp Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Daniel Janney is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Dynavax Technologies Corp do?

Who are the key executives at Dynavax Technologies Corp?

Daniel Janney is the director of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include President & COO David F Novack , 10 percent owner Deep Track Biotechnology Master Fund, Ltd. , and VP & Chief Accounting Officer Joseph Anthony Metzinger .

Dynavax Technologies Corp (DVAX) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 200,784 shares made by David F Novack , a net sale of 2,065,137 shares made by Deep Track Biotechnology Master Fund, Ltd. , and a net purchase of 3,800 shares made by Scott Dunseth Myers .

In summary, during the past 3 months, insiders sold 0 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,265,921 shares of Dynavax Technologies Corp (DVAX) were sold and 3,800 shares were bought by its insiders, resulting in a net sale of 2,262,121 shares.

Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dynavax Technologies Corp Insider Transactions

No Available Data

What does Cutera Inc do?

Who are the key executives at Cutera Inc?

Daniel Janney is the 10 percent owner of Cutera Inc. Other key executives at Cutera Inc include EVP & Chief Technology Officer Michael Karavitis , Interim Chief Financial Office Stuart Drummond , and Chief Operating Officer Jeffrey S Jones .

Cutera Inc (CUTRQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cutera Inc (CUTRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cutera Inc (CUTRQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cutera Inc (CUTRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cutera Inc Insider Transactions

No Available Data

What does Avadel Pharmaceuticals PLC do?

Who are the key executives at Avadel Pharmaceuticals PLC?

Daniel Janney is the 10 percent owner of Avadel Pharmaceuticals PLC. Other key executives at Avadel Pharmaceuticals PLC include Chief Operating Officer Susan Rodriguez , Chief Financial Officer Thomas S Mchugh , and director & Chief Executive Officer Greg J Divis .

Avadel Pharmaceuticals PLC (AVDL) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Avadel Pharmaceuticals PLC (AVDL). Other recent insider transactions involving Avadel Pharmaceuticals PLC (AVDL) include a net sale of 11,112,052 shares made by Weiss Asset Management Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Avadel Pharmaceuticals PLC (AVDL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,112,052 shares of Avadel Pharmaceuticals PLC (AVDL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,112,052 shares.

Avadel Pharmaceuticals PLC (AVDL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avadel Pharmaceuticals PLC Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Daniel Janney is the 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Vice President & Finance (PAO) Yuliya Rueb , Chief Operating Officer Daniel Bensen , and director & 10 percent owner Robert J More .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Daniel Janney made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 281,000 shares made by Daniel Bensen , a net purchase of 1,561,335 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 75,687 shares made by Gilla Kaplan .

In summary, during the past 3 months, insiders sold 0 shares of Tyra Biosciences Inc (TYRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 613,558 shares of Tyra Biosciences Inc (TYRA) were sold and 1,561,335 shares were bought by its insiders, resulting in a net purchase of 947,777 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

Daniel Janney Mailing Address

Above is the net worth, insider trading, and ownership report for Daniel Janney. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Daniel Janney's mailing address is: Jackson Wy 83002.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.